SHARE

Angelini Pharma acquires Catalyst Pharmaceuticals for $4.1bn to enter US market

The Italian drugmaker is acquiring Florida-based Catalyst Pharmaceuticals for $4.1bn, marking its entry into the US pharmaceutical market. The transaction is being advised by major law firms including Kirkland & Ellis, Hogan Lovells and Linklaters.

Certification Note

Certified B Corporation” is a trademark licensed by B Lab, a private non-profit organization, to companies like ours that have successfully completed the B Impact Assessment (“BIA”) and therefore meet the requirements set by B Lab for social and environmental performance, accountability, and transparency. It is specified that B Lab is not a conformity assessment body as defined by Regulation (EU) No 765/2008, nor is it a national, European, or international standardization body as per Regulation (EU) No 1025/2012. The criteria of the BIA are distinct and independent from the harmonized standards resulting from ISO norms or other standardization bodies, and they are not ratified by national or European public institutions.